Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oliver A Sartor

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Urology|October 7, 2014
Reply: To PMID 25283701Jonathan L Silberstein, Oliver A Sartor
The Lancet. Oncology|January 5, 2017
Biosimilar and generic cancer drugs unlikely to bend cost curve in the USACharles L Bennett, Oliver A Sartor, James O Armitage, et al.
The Lancet. Oncology|March 11, 2015
Japanese regulatory authority's perspective on biosimilars - authors' replyCharles L Bennett, Brian Chen, Terhi Hermanson, et al.
Case Reports in Hematology|February 25, 2020
A Case Report with Severe Thrombocytopenia Induced by AxitinibUlkuhan I Koksal, Janeiro Goffin, Brian Lewis, et al.
Carcinogenesis|January 5, 2008
Interactions of cytokine gene polymorphisms in prostate cancer riskJovanny Zabaleta, Hui-Yi Lin, Rosa A Sierra, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2025
PSMA+ Extracellular Vesicles Are a Biomarker for SABR in Oligorecurrent Prostate Cancer: Analysis from the STOMP-like and ORIOLE Trial CohortsJack R Andrews, Yohan Kim, Edlira Horjeti, et al.
The Oncologist|February 15, 2021
The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse ReactionsCharles L Bennett, Sumimasa Nagai, Andrew C Bennett, et al.
European Urology|July 3, 2026
Diagnosis and Staging of Patients with Prostate Cancer: Report from the 2025 Advanced Prostate Cancer Consensus Conference (APCCC) DiagnosticsStefano Fanti, Fabio Turco, Bertrand Tombal, et al.
European Urology|December 9, 2022
Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022Silke Gillessen, Alberto Bossi, Ian D Davis, et al.
European Urology|October 11, 2024
Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)Silke Gillessen, Fabio Turco, Ian D Davis, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Urology|October 7, 2014
Reply: To PMID 25283701Jonathan L Silberstein, Oliver A Sartor
The Lancet. Oncology|January 5, 2017
Biosimilar and generic cancer drugs unlikely to bend cost curve in the USACharles L Bennett, Oliver A Sartor, James O Armitage, et al.
The Lancet. Oncology|March 11, 2015
Japanese regulatory authority's perspective on biosimilars - authors' replyCharles L Bennett, Brian Chen, Terhi Hermanson, et al.
Case Reports in Hematology|February 25, 2020
A Case Report with Severe Thrombocytopenia Induced by AxitinibUlkuhan I Koksal, Janeiro Goffin, Brian Lewis, et al.
Carcinogenesis|January 5, 2008
Interactions of cytokine gene polymorphisms in prostate cancer riskJovanny Zabaleta, Hui-Yi Lin, Rosa A Sierra, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2025
PSMA+ Extracellular Vesicles Are a Biomarker for SABR in Oligorecurrent Prostate Cancer: Analysis from the STOMP-like and ORIOLE Trial CohortsJack R Andrews, Yohan Kim, Edlira Horjeti, et al.
The Oncologist|February 15, 2021
The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse ReactionsCharles L Bennett, Sumimasa Nagai, Andrew C Bennett, et al.
European Urology|July 3, 2026
Diagnosis and Staging of Patients with Prostate Cancer: Report from the 2025 Advanced Prostate Cancer Consensus Conference (APCCC) DiagnosticsStefano Fanti, Fabio Turco, Bertrand Tombal, et al.
European Urology|December 9, 2022
Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022Silke Gillessen, Alberto Bossi, Ian D Davis, et al.
European Urology|October 11, 2024
Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)Silke Gillessen, Fabio Turco, Ian D Davis, et al.
Pageof 1